Investigating the role of ITCH in melanoma and its impact on cancer treatment
Characterizing oncogenic function of ITCH in melanoma
This study is looking at a protein called ITCH to see how it helps melanoma grow and affects the immune system around tumors, with the hope of finding new ways to treat patients with melanoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10914035 on NIH RePORTER |
What this research studies
This research focuses on understanding the function of the ITCH protein in melanoma, particularly its role in activating oncogenic pathways and influencing the immune environment of tumors. The study aims to characterize how ITCH affects signaling pathways in melanoma cells and its potential to create an immunosuppressive environment that aids tumor growth. By exploring these mechanisms, the research seeks to identify ITCH as a target for new therapeutic strategies that could improve treatment outcomes for patients with melanoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with BRAF wild-type melanoma who may benefit from novel therapeutic strategies targeting ITCH.
Not a fit: Patients with melanoma that has mutations in the BRAF gene may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for melanoma patients by targeting the ITCH protein to enhance immune responses against tumors.
How similar studies have performed: Previous research has shown promising results in targeting similar oncogenic pathways in cancer treatment, suggesting that this approach may yield significant advancements.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Wan, Lixin — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Wan, Lixin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.